西安诺和达生物科技有限公司
+86 13662665103 Mon–Fri, 09:00–18:00 GMT+8 Contact Us sales@nhdbio.com
Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司

Quote list

Review quantities before sending your request.

View full quote listContinue browsing productsThis is an enquiry list, not a checkout. No payment is taken.
 Request an Account

Canonical product evidence map

Retatrutide Evidence Map

A source-linked map separating peer-reviewed human trials, trial registries, sponsor status reports, mechanism studies and regulatory context for retatrutide.

Browse source recordsOpen product dossier
22
unique source records
5
research types
2022–2026
source-year range

Evidence distribution

See the source mix before reading the conclusions.

A large record count does not imply mature human evidence. The model and source type determine which question a record can answer.

Research type

Research record9
Registry or sponsor record5
Regulatory or database record3
Clinical trial3
Laboratory study2

Study model

Not specified9
Registry / sponsor5
Regulatory / database3
Human3
In vitro1
Analytical / material1

Source-linked records

22 records connected to Retatrutide

Records are deduplicated by canonical source URL and keep their model, type and evidence-tier labels visible.

Evidence boundary

A source set is not a clinical recommendation.

  • Human, animal, in-vitro, analytical, registry and regulatory records remain separate evidence categories.
  • A published intervention or approved finished medicine does not verify the identity or quality of a catalog research lot.
  • Record inclusion does not mean every finding has been independently replicated or applies outside its stated population and model.

Continue researching

Move between identity, status and analytical meaning.

Product dossierVerified statusAnalytical methodsAdvanced filters

Retatrutide research: which studies answer your question?

When looking into Retatrutide research, start by choosing your question: body weight, blood glucose, or receptor structure? Below, three types of published studies are separated to avoid treating different measures as the same scorecard.

Weight studies: look at population and observation time

The 2023 phase 2 obesity trial enrolled 338 adults, compared several Retatrutide regimens with placebo, and followed participants for 48 weeks. The weight changes apply to that trial population and those regimens. Read them alongside the statistical analysis, participant withdrawals, and safety findings.

Blood glucose studies: the main questions are not the same

The phase 2 type 2 diabetes study published that year examined blood glucose, body weight, and other outcomes in its own population. HbA1c reflects blood glucose over a period of time. It is a different measure from percentage weight change and answers a different primary question.

Structural studies: helping understand how the molecule binds

A 2024 receptor structure study discussed how three receptors recognize Retatrutide. It is suitable for explaining mechanism, but it cannot be placed in the same column as the 48 week weight trial to judge which is "more effective."

How should this map continue to be expanded?

New records should provide the registration number, original source, publication date, study subjects, comparison groups, primary endpoints, and analysis time points. Preliminary sponsor announcements, conference abstracts, formal papers, and registry results should be labeled separately, and the same record should be updated when a new version appears.

The current cards are a reading entry point, not an exhaustive list of all Retatrutide research. The specific study status should be checked by clicking the corresponding original record.

Find Retatrutide research by question
Phase 2 obesity trial, 2023What readers should look for: Weight change, population, and timeWhat not to mix together: Results that everyone can achieve
Phase 2 type 2 diabetes trial, 2023What readers should look for: Blood glucose measures such as HbA1c and comparison groupsWhat not to mix together: Directly comparing highs and lows with another trial
Three-receptor structure study, 2024What readers should look for: Recognition and binding mechanismWhat not to mix together: Human effect percentages
Teaching summary. Check the explanation and original sources; this is not a to-scale molecular model or a product test result.
Find Retatrutide research by question
StudyWhat readers should look forWhat not to mix together
Phase 2 obesity trial, 2023Weight change, population, and timeResults that everyone can achieve
Phase 2 type 2 diabetes trial, 2023Blood glucose measures such as HbA1c and comparison groupsDirectly comparing highs and lows with another trial
Three-receptor structure study, 2024Recognition and binding mechanismHuman effect percentages

Separate group estimates from individual outcomes

The 2023 phase 2 obesity trial enrolled 338 adults. At 48 weeks, least-squares mean weight change was −24.2% in the 12 mg trial group and −2.1% with placebo. These are model-adjusted group estimates, not individual outcomes or effects of catalog materials. Read the gastrointestinal adverse events and other safety observations alongside weight results.

Original sources and further reading

Sources checked on 2026-10-13. Findings apply to the models and materials studied. Batch quality requires records for the actual batch.

Related research materials

RetatrutideView material identity, specifications, and packaging; documentation needs can be raised with an inquiry.

Inquire about specifications, quantities, and required materials